Please login to the form below

Immunomedics

This page shows the latest Immunomedics news and features for those working in and with pharma, biotech and healthcare.

Seattle Genetics claims key US approval for Adcetris

The approval is also important for Seattle after its aborted $2bn deal to license Immunomedics’IMMU-132, another ADC drug for triple-negative breast cancer (TNBC), which was scuppered by a ... shareholder and claimed the jobs of Immunomedics’CEO

Latest news

Activists torpedo Immunomedics deal with Seattle Genetics

Activists torpedo Immunomedics deal with Seattle Genetics. venBio says deal will enrich CEO at shareholders' expense. ... Immunomedics shareholders - pointing out that the company has failed to bring any products to market in its 35-year history.
Move on Immunomedics board puts Seattle Genetics deal in doubt

Move on Immunomedics board puts Seattle Genetics deal in doubt. Four venBio candidates voted to the board which gives group a majority. ... and punishing Immunomedics for failing to bring any products to market in its 35-year history.
Seattle Genetics signs $2bn deal for Immunomedics' cancer drug

Seattle Genetics signs $2bn deal for Immunomedics' cancer drug. Buys rights to breast cancer drug candidate that could be be in line for FDA approval by year end. ... Immunomedics has signed up Seattle Genetics as the licensee for its triple-negative
Pacira CEO David Stack joins board of health monitoring firm Medivo

He has also held senior positions at Immunomedics and Roche. “ This is a perfect time for me to reconnect with Sundeep and his management team at Medivo,” Stack said. “
Lupus – a 'great imitator'

Targeting B-cell activation appears to be the chosen route for the majority of treatments for SLE, including epratuzumab (Epratucyn, Immunomedics/UCB).

More from news
Approximately 3 fully matching, plus 4 partially matching documents found.

Latest Intelligence

Deal Watch January 2018

Collaboration, licence. 310. Immunomedics/ Royalty Pharma. Royalty rights to sacituzumab govitecan (IMMU- 132) across all indications. ... The whole episode resulted in the resignation of the Immunomedics CEO and CSO.
Deal Watch March 2017

In an unusual development, the recent licensing deal between Immunomedics and Seattle Genetics, whereby Seattle Genetics is to pay $250m in cash, up to $1.7bn in milestones, and royalties, has ... The activist investor venBio, which has recently gained
Deal Watch February 2017

Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... Acquisition - company. 2, 475.
Pharma deals during October 2013

The dispute between the parties concerns development delays that Immunomedics argued were material breach of the agreement. ... On termination, all rights revert back to Immunomedics and it is expected that arbitration will continue in parallel with

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Senior Account Manager / Account Director: Great salary and bebefits

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Senior Medical Writer: Great salary and benefits

Scientific Director: Great salary and bebefits

Senior Medical Writer: Great salary and bebefits

Account Manager – Med Comms – London: Salary TBC

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Editor – Medical Education Agency – Bucks: Salary TBC

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Senior Programme Executive: Salary TBC

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Medical Writer - (London, Brighton or Copenhagen): Competitive

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Senior Account Manager or AD - Medical Communications: Salary TBC

Senior Account Manager – Med Comms – Kent: Salary TBC

Editorial Director – Medical Education – Oxford: Negotiable

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

No incentive for a cure: The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...